Antiplatelet Agents Can Promote Two-Peaked Thrombin Generation in Platelet Rich Plasma: Mechanism and Possible Applications

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Tarandovskiy, Ivan D ^a   Artemenko, Elena O ^a   Panteleev, Mikhail A ^a,b,c,d   Sinauridze, Elena I ^a,b   Ataullakhanov, Fazoil I ^a,b,c,d  

^a CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

^b NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^c MOSCOW STATE UNIVERSITY   (Russian Federation)

^d Federal Research and Clinical Center of Pediatric Hematology   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; ARGININE; BLOOD CLOTTING FACTOR 10A; DIMETHYL SULFOXIDE; GLYCINE; PADGEM PROTEIN; PHOSPHATIDYLSERINE; PROSTAGLANDIN E1; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROLYSIS; LONG TERM EXPOSURE; NORMAL HUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA;

ALPROSTADIL; COUMARINS; FACTOR V; FACTOR XA; FLOW CYTOMETRY; HEMOSTATICS; HUMANS; OLIGOPEPTIDES; P-SELECTIN; PHOSPHATIDYLSERINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET-RICH PLASMA; THROMBIN; THROMBOPLASTIN;

EID: 84873548229     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055688     Document Type: Article

References (39)

1. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S, (2000) The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 83: 589-591.
2. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, et al. (2002) The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 32: 249-253.
3. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, et al. (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33: 4-15.
4. Vanschoonbeek K, Feijge MA, Van Kampen RJ, Kenis H, Hemker HC, et al. (2004) Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2: 476-484.
5. van der Meijden PE, Feijge MA, Giesen PL, Huijberts M, van Raak LP, et al. (2005) Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost 93: 1128-1136.
6. Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, et al. (2011) Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 118: 1952-1961.
7. Siegemund T, Petros S, Siegemund A, Scholz U, Engelmann L, (2003) Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 90: 781-786.
8. Santagostino E, Mancuso ME, Tripodi A, Chantarangkul V, Clerici M, et al. (2010) Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 8: 737-743.
9. Tappenden KA, Gallimore MJ, Evans G, Mackie IJ, Jones DW, (2007) Thrombin generation: a comparison of assays using platelet-poor and-rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism. Br J Haematol 139: 106-112.
10. Rugeri L, Beguin S, Hemker C, Bordet JC, Fleury R, et al. (2007) Thrombin-generating capacity in patients with von Willebrand's disease. Haematologica 92: 1639-1646.
11. Tardy-Poncet B, Piot M, Chapelle C, France G, Campos L, et al. (2009) Thrombin generation and heparin-induced thrombocytopenia. J Thromb Haemost 7: 1474-1481.
12. Gerotziafas GT, Depasse F, Chakroun T, Samama MM, Elalamy I, (2004) Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 91: 531-537.
13. Wagenvoord R, Hemker PW, Hemker HC, (2006) The limits of simulation of the clotting system. J Thromb Haemost 4: 1331-1338.
14. Bevers EM, Comfurius P, Dekkers DW, Zwaal RF, (1999) Lipid translocation across the plasma membrane of mammalian cells. Biochim Biophys Acta 1439: 317-330.
15. Kalafatis M, Swords NA, Rand MD, Mann KG, (1994) Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes. Biochim Biophys Acta 1227: 113-129.
16. Butenas S, Cawthern KM, van't Veer C, DiLorenzo ME, Lock JB, et al. (2001) Antiplatelet agents in tissue factor-induced blood coagulation. Blood 97: 2314-2322.
17. Kotova YN, Ataullakhanov FI, Panteleev MA, (2008) Formation of coated platelets is regulated by the dense granule secretion of adenosine 5′diphosphate acting via the P2Y12 receptor. J Thromb Haemost 6: 1603-1605.
18. Topalov NN, Kotova YN, Vasil'ev SA, Panteleev MA, (2012) Identification of signal transduction pathways involved in the formation of platelet subpopulations upon activation. Br J Haematol 157: 105-115.
19. Panteleev MA, Ananyeva NM, Greco NJ, Ataullakhanov FI, Saenko EL, (2005) Two subpopulations of thrombin-activated platelets differ in their binding of the components of the intrinsic factor X-activating complex. J Thromb Haemost 3: 2545-2553.
20. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, et al. (2007) Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 97: 425-434.
21. Brammer JP, Maguire MH, (1984) Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid. Br J Pharmacol 82: 61-72.
22. Holtz GC, Davis RB, (1972) Inhibition of human platelet aggregation by dimethylsulfoxide, dimethylacetamide, and sodium glycerophosphate. Proc Soc Exp Biol Med 141: 244-248.
23. Asmis L, Tanner FC, Sudano I, Luscher TF, Camici GG, (2010) DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents? Biochem Biophys Res Commun 391: 1629-1633.
24. Iyu D, Juttner M, Glenn JR, White AE, Johnson AJ, et al. (2011) PGE1 and PGE2 modify platelet function through different prostanoid receptors. Prostaglandins Other Lipid Mediat 94: 9-16.
25. Gumbel EJ (1954) Statistical theory of extreme values and some practical applications; a series of lectures. Washington,: U.S. Govt. Print. Office. viii, 51 p. p.
26. The Subcommittee on Control of Anticoagulation of the SSC of the ISTH (2011) Towards a recommendation for the standardization of the measurement of platelet-dependent thrombin generation. J Thromb Haemost 9: 1859-1861.
27. Jacob SW, de la Torre JC, (2009) Pharmacology of dimethyl sulfoxide in cardiac and CNS damage. Pharmacol Rep 61: 225-235.
28. Mueller LP, Theurich S, Christopeit M, Grothe W, Muetherig A, et al. (2007) Neurotoxicity upon infusion of dimethylsulfoxide-cryopreserved peripheral blood stem cells in patients with and without pre-existing cerebral disease. Eur J Haematol 78: 527-531.
29. Chen-Plotkin AS, Vossel KA, Samuels MA, Chen MH, (2007) Encephalopathy, stroke, and myocardial infarction with DMSO use in stem cell transplantation. Neurology 68: 859-861.
30. Martin-Henao GA, Resano PM, Villegas JM, Manero PP, Sanchez JM, et al. (2010) Adverse reactions during transfusion of thawed haematopoietic progenitor cells from apheresis are closely related to the number of granulocyte cells in the leukapheresis product. Vox Sang 99: 267-273.
31. Hoang BX, Tran DM, Tran HQ, Nguyen PT, Pham TD, et al. (2011) Dimethyl sulfoxide and sodium bicarbonate in the treatment of refractory cancer pain. J Pain Palliat Care Pharmacother 25: 19-24.
32. Kozek-Langenecker SA, Wanzel O, Berger R, Kettner SC, Coraim F, (1998) Increased anticoagulation during cardiopulmonary bypass by prostaglandin E1. Anesth Analg 87: 985-988.
33. Chatziioannou A, Dalakidis A, Katsenis K, Koutoulidis V, Mourikis D, (2012) Intra-arterial prostaglandin e(1) infusion in patients with rest pain: short-term results. ScientificWorldJournal 2012: 803678.
34. Cawello W, Leonhardt A, Schweer H, Seyberth HW, Bonn R, et al. (1995) Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. Br J Clin Pharmacol 40: 273-276.
35. Kreutz RP, Nystrom P, Kreutz Y, Miao J, Kovacs R, et al. (2012) Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin. Platelets.
36. Roberts W, Magwenzi S, Aburima A, Naseem KM, (2010) Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascade. Blood 116: 4297-4306.
37. Neubauer H, Lask S, Engelhardt A, Mugge A, (2008) How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 99: 357-362.
38. Andre P, LaRocca T, Delaney SM, Lin PH, Vincent D, et al. (2003) Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 108: 2697-2703.
39. Maloney SF, Brass LF, Diamond SL, (2010) P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions. Integr Biol (Camb) 2: 183-192.